4.7 Review

The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V

Journal

Publisher

MDPI
DOI: 10.3390/ijms23158283

Keywords

vascular endothelium; coagulation; embryo; von Willebrand factor; factor VIII; factor V; homeostasis; coagulopathies; treatment

Funding

  1. Association for Research and Cure of Factor V deficiency (ASDEFAV) [ASDEFAV/2021-23]
  2. Complutense University of Madrid and Banco Santander [CT63/19-CT64/19]
  3. Junta de Andalucia Research Funding Program [PAI-BIO/295]

Ask authors/readers for more resources

The vascular endothelium plays a crucial role in hemostasis, maintaining a delicate balance between procoagulant and anticoagulant proteins, as well as fibrinolytic and antifibrinolytic factors. Coagulation disorders can be caused by mutations in coagulation factors or disruptions in the regulatory mechanisms. Treatment options include replacement and nonreplacement therapies, as well as administration of antifibrinolytic agents. Targeted therapies, such as monoclonal antibodies and interfering RNA therapies, are also being developed. The treatment approach for thrombophilia, disseminated intravascular coagulation, and severe thrombophilia varies depending on the specific condition.
The vascular endothelium has several important functions, including hemostasis. The homeostasis of hemostasis is based on a fine balance between procoagulant and anticoagulant proteins and between fibrinolytic and antifibrinolytic ones. Coagulopathies are characterized by a mutation-induced alteration of the function of certain coagulation factors or by a disturbed balance between the mechanisms responsible for regulating coagulation. Homeostatic therapies consist in replacement and nonreplacement treatments or in the administration of antifibrinolytic agents. Rebalancing products reestablish hemostasis by inhibiting natural anticoagulant pathways. These agents include monoclonal antibodies, such as concizumab and marstacimab, which target the tissue factor pathway inhibitor; interfering RNA therapies, such as fitusiran, which targets antithrombin III; and protease inhibitors, such as serpinPC, which targets active protein C. In cases of thrombophilia (deficiency of protein C, protein S, or factor V Leiden), treatment may consist in direct oral anticoagulants, replacement therapy (plasma or recombinant ADAMTS13) in cases of a congenital deficiency of ADAMTS13, or immunomodulators (prednisone) if the thrombophilia is autoimmune. Monoclonal-antibody-based anti-vWF immunotherapy (caplacizumab) is used in the context of severe thrombophilia, regardless of the cause of the disorder. In cases of disseminated intravascular coagulation, the treatment of choice consists in administration of antifibrinolytics, all-trans-retinoic acid, and recombinant soluble human thrombomodulin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available